Cagrilintide vs Semaglutide: Mechanism Compared
This is the comparison where the two compounds aren't variations on a theme — they work through different hormone systems entirely, which is exactly why they're studied together.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Hormone system | Amylin | Incretin (GLP-1) |
| Receptor targets | Amylin / calcitonin receptors | GLP-1 receptor |
| Class | Long-acting amylin analog | GLP-1 receptor agonist |
| Most-studied design | Combined with semaglutide | Combined with cagrilintide |
Unlike the GLP-1 family, cagrilintide is not an incretin compound. It is an analog of amylin, a hormone co-secreted with insulin that acts on amylin and calcitonin receptors in the brainstem and hypothalamus. Semaglutide acts on the GLP-1 receptor. These are separate signaling systems.
Because the two reach overlapping research endpoints through different receptors, the most-studied question in the literature isn't cagrilintide versus semaglutide — it's cagrilintide *plus* semaglutide, combining an amylin signal with a GLP-1 signal in one protocol.
So the comparison is less 'which one' and more 'what each pathway contributes.' That's the framing the published combination research is built around.
This compares molecular mechanism and receptor class from the published literature only, not efficacy, potency, or outcomes. All Boulder Labs products are for laboratory research use only. Not for human consumption.
Common questions
What is the difference between cagrilintide and semaglutide?
Cagrilintide is a long-acting amylin analog acting on amylin and calcitonin receptors. Semaglutide is a GLP-1 receptor agonist. They work through entirely different hormone systems — amylin versus the incretin GLP-1 pathway.
Why are cagrilintide and semaglutide studied together?
Because they reach overlapping metabolic endpoints through different receptors, research has focused on combining them — an amylin signal alongside a GLP-1 signal — rather than treating them as alternatives.